Skip to main content

Advertisement

SpringerLink
Log in

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) plays an important role in immune tolerance. In some malignancies, the evidences were given to show that overexpression of IDO was related to poor prognosis of cancer patients.

Methods

In this study, we investigated IDO expression in hepatocellular carcinoma (HCC) cell lines and 138 primary HCC clinical surgical specimens, and correlation of IDO expression with clinical outcomes and prognosis of HCC patients.

Results

Reverse transcription-PCR analysis showed that in vitro IDO expression in HCC cell lines and non-cancerous liver cell line were dependent on IFN-γ. Immunohistochemical detection revealed that IDO was overexpressed in 49 of 138 (35.5%) tumor resection samples, whereas 89 of 138 (64.5%) cases showed weak immunostaining. IDO overexpression was significantly correlated with high metastasis rates (P = 0.049). Kaplan–Meier survival curves showed that overexpression of IDO resulted in significantly poor prognosis (P = 0.017, log-rank test). Multivariate Cox’s analysis showed that IDO expression was an independent prognostic factor for overall survival of HCC patients (P = 0.010).

Conclusion

Our data indicated that IDO may be a novel favorable prognostic indicator and candidate adjuvant therapeutic target for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Astigiano S, Morandi B, Costay R, Mastracciz L, D’Agostino A, Rattob GB, Melioli G, Frumento G (2005) Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung Cancer. Neoplasia 7:390–396

    Article  PubMed  CAS  Google Scholar 

  • Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144–1151

    Article  PubMed  CAS  Google Scholar 

  • Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867

    Article  PubMed  CAS  Google Scholar 

  • Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I, Horenstein AL, Fiore F, Massaia M, Colombo MP, Baccarani M, Lemoli RM (2007) Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells. Blood 109:2871–2877

    PubMed  CAS  Google Scholar 

  • Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206–1212

    Article  PubMed  CAS  Google Scholar 

  • Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752–6761

    PubMed  CAS  Google Scholar 

  • Finger EB, Bluestone JA (2002) When ligand becomes receptor-tolerance via B7 signaling on DCs. Nat Immunol 3:1056–1057

    Article  PubMed  CAS  Google Scholar 

  • Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151–155

    Article  PubMed  CAS  Google Scholar 

  • Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097–1101

    Article  PubMed  CAS  Google Scholar 

  • Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokora K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for dendometrial cancer. B J Cancer 95:1555–1561

    Article  CAS  Google Scholar 

  • Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH (2003) Pattern of recruitment of immunoregulatory antigen presenting cells in malignant melanoma. Lab Invest 83:1457–1466

    Article  PubMed  CAS  Google Scholar 

  • Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11:107–112

    PubMed  CAS  Google Scholar 

  • Mapara MJ, Sykes M (2004) Tolerance and cancer mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151

    Article  PubMed  CAS  Google Scholar 

  • Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:169–473

    Article  Google Scholar 

  • Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774

    Article  PubMed  CAS  Google Scholar 

  • Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154

    Article  PubMed  CAS  Google Scholar 

  • Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363–1372

    Article  PubMed  CAS  Google Scholar 

  • Munn DH, Sharma MD, Mellor AL (2004a) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100–4110

    PubMed  CAS  Google Scholar 

  • Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004b) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280–290

    PubMed  CAS  Google Scholar 

  • Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R Jr, Slingluff CL, Mellor AL (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870

    Article  PubMed  CAS  Google Scholar 

  • Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S (2007) Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 98:874–881

    Article  PubMed  CAS  Google Scholar 

  • Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11:6030–6039

    Article  PubMed  CAS  Google Scholar 

  • Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F, Bianchi R, Velardi E, Perruccio K, Velardi A, Bronte V, Fioretti MC, Grohmann U (2006) Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107:2846–2854

    Article  PubMed  CAS  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  • Takikawa O, Yoshida R, Kido R, Hayaishi O (1986) Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261:3648–3653

    PubMed  CAS  Google Scholar 

  • Tang ZY (2000) Hepatocellular carcinoma. J Gastroenterol Hepatol 15(Suppl):1–7

    Article  Google Scholar 

  • Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274

    Article  PubMed  CAS  Google Scholar 

  • von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, Fiore F, Roth U, Beyer M, Debey S, Wickenhauser C, Hanisch FG, Schultze JL (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108:228–237

    Article  Google Scholar 

  • Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Yuexiu District, 510060, Guangzhou, Guangdong, People’s Republic of China

    Ke Pan, Hui Wang, Hua-kun Zhang, De-sheng Weng, Jun Zhou, Wei Huang, Jian-jun Li, Hai-feng Song & Jian-chuan Xia

  2. Department of Hepatobilary Oncology, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People’s Republic of China

    Min-shan Chen

Authors
  1. Ke Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min-shan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hua-kun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. De-sheng Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hai-feng Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jian-chuan Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-chuan Xia.

Additional information

K. Pan and H. Wang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pan, K., Wang, H., Chen, Ms. et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134, 1247–1253 (2008). https://doi.org/10.1007/s00432-008-0395-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0395-1

Keywords

Search

Navigation